Clinical studies recruiting near Chelsea

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 3 · Eli Lilly and Company · NCT07218380 This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide W
Phase 3 · Pfizer · NCT07028853 A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation Dur
Phase 2 · National Institute of Allergy and Infectious Diseases (NIAID · NCT05719441 A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line
Phase 3 · Merck Sharp & Dohme LLC · NCT06136559 Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · Merck Sharp & Dohme LLC · NCT06393374 MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · Trinity Health IHA Medical Group Hematology Oncology - Chels · National Cancer Institute (NCI) · NCT05564390 Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · Chelsea Hospital · NRG Oncology · NCT05624996 A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
Phase 3 · Alfasigma S.p.A. · NCT06865417 Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel
Phase 2 · Trinity Health IHA Medical Group Hematology Oncology - Chels · National Cancer Institute (NCI) · NCT07437950 A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spe
Phase 2 · Relay Therapeutics, Inc. · NCT06789913 Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C
Phase 3 · Trinity Health IHA Medical Group Hematology Oncology - Chels · Alliance for Clinical Trials in Oncology · NCT07321652 Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/Phase 2 · Revolution Medicines, Inc. · NCT07397338 Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov
Phase 3 · Amgen · NCT07037433 Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Phase 1/Phase 2 · Pfizer · NCT07421700 Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Phase 3 · Summit Therapeutics · NCT07228832 COlorectal BReath Analysis (COBRA2)
Phase N/A · Imperial College London · NCT05844514 Post-Market Study to Assess iTind Safety in Comparison to UroLift
NA · Olympus Corporation of the Americas · NCT04757116 Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
NA · Chelsea Hospital · Alliance for Clinical Trials in Oncology · NCT07091617 Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS
Phase 3 · Eli Lilly and Company · NCT06890598 A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Phase 3 · Janssen Research & Development, LLC · NCT07499232 A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorecta
Phase 1 · Hoffmann-La Roche · NCT04929223 Visugromab in Cachexia International Trial
Phase 2/Phase 3 · CatalYm GmbH · NCT07112196 A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants Wit
Phase 3 · Merck Sharp & Dohme LLC · NCT06077760 Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM
Phase 2 · Trinity Health IHA Medical Group Hematology Oncology - Chels · SWOG Cancer Research Network · NCT06769126 Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Phase 3 · Chelsea Hospital · NRG Oncology · NCT05946213 A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in Fi
Phase 3 · Amgen · NCT07005128 Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
NA · European Organisation for Research and Treatment of Cancer - · NCT04498767 A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metast
Phase 1/Phase 2 · Merck Sharp & Dohme LLC · NCT05562830 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · Chelsea Hospital · NRG Oncology · NCT05174169 Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati
Phase 3 · Trinity Health IHA Medical Group Hematology Oncology - Chels · Alliance for Clinical Trials in Oncology · NCT06931340

Look up another city

Look up another condition